4 times Within The Past Five Days, Adamis Pharmaceuticals Corporation (ADMP) Hit A New High

0
7

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) finished Wednesday with a subtraction of -$0.1 to close at $0.26, a downside of -28.26 percent. An average of 1,551,960 shares of common stock have been traded in the last five days. There was a fall of -$0.0751 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 624,660 shares traded, while the 50-day average volume stands at 698,534.

ADMP stock has decreased by -19.38% in the last month. The company shares reached their 1-month lowest point of $0.1810 on 09/21/22. With the stock rallying to its 52-week high on 01/10/22, shares of the company touched a low of $0.31 and a high of $1.48 in 52 weeks. It has reached a new high 3 times so far this year and lost -57.37% or -$0.3471 in price. In spite of this, the price is down -82.57% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Insider Transactions

188 days have passed since Adamis Pharmaceuticals Corporation (ADMP) last reported insider trading activity. Moss Ronald B., who is Chief Medical Officer, most recently acquired $8,199 shares at $0.60 per share on Mar 18. In this transaction, the insider spent $4,949. SVP and Chief Business Officer, Marguglio David J., disposed of 11,859 shares at a price of $0.60 on Mar 18. The insider now owns more than $7,117 worth of shares. Prior to that, President & CEO CARLO DENNIS J PHD went on to Sale 10,490 shares at $0.60 each on Mar 18. An amount of $6,287 was transacted.

Valuation Metrics

Adamis Pharmaceuticals Corporation (ADMP) stock’s beta is 1.03. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 53.47, the price-to-book (PB) ratio at 5.16.

Financial Health

The quick ratio of Adamis Pharmaceuticals Corporation for the three months ended June 29 was 1.50, and the current ratio was 1.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at -$4.66 million compared to revenue of $2.21 million.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$8.4 million in the quarter, while revenues were shrunk -10.83%. The analyst consensus anticipated Adamis Pharmaceuticals Corporation’s latest quarter earnings to come in at -$0.03 per share, but it turned out to be -$0.06, a -100.00% surprise. For the quarter, EBITDA amounted to -$7.81 million. Shareholders own equity worth $149.98 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Adamis Pharmaceuticals Corporation (ADMP) price momentum. RSI 9-day as of the close on 21 September was 26.38%, suggesting the stock is oversold, with historical volatility in this time frame at 182.30%.

As of today, ADMP’s price is $0.3353 -22.55% or -$0.0751 from its 5-day moving average. ADMP is currently trading -19.83% lower than its 20-day SMA and -38.60% lower than its 100-day SMA. However, the stock’s current price level is -47.66% below the SMA50 and -62.17% below the SMA200.

The stochastic %K and %D were 70.86% and 72.67%, respectively, and the average true range (ATR) was 0.0404. With the 14-day stochastic at 39.84% and the average true range at 0.0342, the RSI (14) stands at 30.14%. The stock has reached -0.0098 on the 9-day MACD Oscillator while the 14-day reading was at -0.0062.

Analyst Ratings

Maxim Group upgraded Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold.

LEAVE A REPLY

Please enter your comment!
Please enter your name here